Medical device maker Boston Scientific beats Q3 revenue estimates on strong US demand
I'm PortAI, I can summarize articles.
Boston Scientific reported a 20.3% increase in Q3 revenue, surpassing analyst expectations with adjusted EPS of $0.75. The company has discontinued sales of ACURATE valve systems globally. For 2025, it anticipates net sales growth of approximately 20% and GAAP EPS between $1.97-$2.01. The cardiovascular segment saw a 22.4% sales increase, driven by strong U.S. demand, which grew 27%. Analysts maintain a "buy" rating, with a median 12-month price target of $125.00, reflecting a 20.1% upside from its recent closing price of $99.90.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments